Patients
edema, NA-AION, cancer, allergy, uveitis, opacity, cataract, glaucoma, retinal pathologies, hypersensitivity, sudden painless loss of monocular vision
SYSTEMIC VASCULITIS, EYE INFLAMMATION, COLLAGEN DISEASE, EDEMA, CANCER, ALLERGY, UVEITIS, OPACITY, CATARACT, MULTIPLE SCLEROSIS, GIANT CELL ARTERITIS, GLAUCOMA, OPTIC NEUROPATHY, HYPERSENSITIVITY, INTRAOCULAR PRESSURE
Patients who presented with acute NA-AION within the first 2 weeks after symptom onset and met the inclusion and exclusion criteria were included after providing written informed consent.The inclusion criteria included patients with acute unilateral NA-AION who presented within the first 2 weeks after symptom onset. NA-AION was defined by at least two of the following clinical characteristics: sudden painless loss of monocular vision; ONH edema; a clear RAPD; patients age of 50 years or older; and the ability to freely provide informed consent and complete the data protection form for study participation.The general exclusion criteria included a medical history, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) values compatible with a diagnosis of giant cell arteritis; evidence of any other etiology justifying optic neuropathy, even in the contralateral eye; a history of systemic vasculitis, multiple sclerosis, collagen disease, or cancer treatments; a positive pregnancy test at baseline in fertile women (for this purpose, menopause of at least 1 year from the baseline visit, bilateral oophorectomy, and/or total hysterectomy with adnexectomy indicated that women were not fertile); hypersensitivity or allergy to any of the active ingredients or excipients of an advanced therapy investigational medicinal product; and participation in any other CT with drugs or diagnostic or therapeutic instruments in the 2 months before inclusion in this study.The ophthalmologic exclusion criteria included a history of uveitis or active eye inflammation; history or evidence of glaucoma or an intraocular pressure (IOP) of 24 mmHg or higher in either eye; media opacity hindering posterior pole examination; retinal pathologies in the affected eye; a history of cataract, vitreous, or glaucoma surgery during the previous 3 months in the affected eye.